The Royal Institution for the Advancement of Learning / Mcgill University

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Pouria Jandaghi

Jörg Hoheisel

Yasser Riazalhosseini

Daniel Scott Auld

Yasser Riaz Alhosseini

Veena Sangwan

The present disclosure provides a novel method for treating pancreatic cancer and pancreatitis in which a combination of a dopamine receptor antagonist (pimozide, haloperidol, and/or L-741,626), 2-deoxy-D-glucose and atorvastatin are used, optionally in combination with gemcitabine.

Pancreatic cancer therapy and diagnosis

The current disclosure relates to methods for treating pancreatic cancer or chronic pancreatitis in a subject comprising administering an antagonist of a dopamine receptor to the subject wherein the dopamine receptor is, in some specific cases dopamine receptor D2 (DRD2). The antagonist in some specific cases is an RNAi construct, an antibody, or a small molecule and in more specific cases pimozide or L-741,626. The disclosure also relates to diagnostic methods comprising the detection of the expression of DRD2 in pancreatic tissue and kits for doing the same.

Growing community of inventors

Montreal, Canada

Pouria Jandaghi